Core Laboratories vs Expro
CLB and XPRO side by side, both in oil and gas field services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLB and XPRO compare
Expro is the larger company, worth 3.7 times as much as Core Laboratories ($1.5B against $414M).
On earnings, Core Laboratories is cheaper: it trades at 26.6× trailing earnings, against 74.9× for Expro.
Core Laboratories grew revenue faster over the last twelve months (−0.15% versus −7.1% for Expro).
Core Laboratories keeps more of each dollar of sales as profit, with a net margin of 3.0% compared with 1.3% at Expro.
Core Laboratories pays a dividend yielding 0.33%; Expro does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLB | XPRO |
|---|---|---|
| Size and price | ||
| Market cap | $414M | $1.5B |
| Share price | $9.04 | $13.49 |
| Change, 1 year | −41.5% | −2.4% |
| Change, 5 years | −62.9% | −18.1% |
| Beta (5Y) | 1.14 | 1.08 |
| Employees | 3,300 | 8,500 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 26.6× (better) | 74.9× |
| P/S | 0.8× (better) | 1.0× |
| P/B | 1.5× | 1.0× (better) |
| EV/EBITDA | 9.5× | 5.4× (better) |
| P/FCF | 40.0× | 13.5× (better) |
| PEG | 1.84 | – |
| FCF yield | 2.5% | 7.4% (better) |
| Fair value | $8.17 | $10.60 |
| Margin of safety | −10.7% (better) | −27.3% |
| Growth | ||
| Revenue growth (TTM) | −0.15% (better) | −7.1% |
| Revenue growth, 5Y average | – | 18.9% |
| Net income growth (TTM) | −51.6% (better) | −70.9% |
| EPS growth (TTM) | −50.0% (better) | −71.0% |
| Profitability | ||
| Gross margin | 19.1% | 22.4% (better) |
| Operating margin | 7.5% (better) | 3.3% |
| Net margin | 3.0% (better) | 1.3% |
| FCF margin | 2.0% | 7.2% (better) |
| Return on equity | 5.7% (better) | 1.4% |
| Return on invested capital | 6.0% (better) | 2.0% |
| Financial health | ||
| Debt / equity | 0.40 (better) | 0.00 |
| Net debt / EBITDA | 1.69 | – |
| Interest coverage | 3.5× | – |
| Current ratio | 2.19 (better) | 2.05 |
| Altman Z-score | 2.57 (better) | 1.94 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 0.33% | – |
| Payout ratio | 11.9% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | 2.5% | 4.3% (better) |
| Shareholder yield | 2.8% | 4.3% (better) |
| Ownership | ||
| Held by institutions | 115% | 101% |
| Held by insiders | 1.5% | 0.00% |
| Insider net buying, 12 months | $53.9K | – |
| Short interest, % of float | 11.0% | 6.2% |
Go deeper
- CLB stock overview
- CLB income statement
- CLB valuation and score
- XPRO stock overview
- XPRO income statement
- XPRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.